2 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow AAA617: new trials by email Literature Review of AAA617 trials Research Report on AAA617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic | Phase 3 | Recruiting | University College, London | 3360 | 2024-06-11 | 2025-09-26 |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg) - Oligometastatic Prostate Cancer (OMPC) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 450 | 2024-03-12 | 2026-10-21 |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1144 | 2021-06-09 | 2026-11-04 |
Novartis Pharmaceuticals (2) · ECOG-ACRIN Cancer Research Group (1) · University College, London (1)
United Kingdom (3) · Austria (2) · Belgium (2) · Canada (2) · China (2) · Czechia (2) · France (2) · Germany (2) · Japan (2) · Netherlands (2) · Singapore (2) · Spain (2) · Switzerland (2) · Taiwan (2) · United States (2)
Louise Brown (1) · Michael Schweizer (1) · Nick James (1)
2023 (1), U10CA180820 (1)